Glenmark Life Sciences Ltd. (ALIVUS) Share Price Rises 6.12% Today

Published: 31 August 2026 at 9:19:50 AM IST

ALIVUS Share Price rose to Rs 1,433.95, up 6.12% from the previous close of Rs 1,351.25, with market capitalisation at Rs 16,589.49 crore. The move placed Glenmark Life Sciences Ltd. among the stocks in news today, and the ALIVUS share price update is relevant because the session also printed an intraday high of Rs 1,433.95 and turnover of Rs 0.47 crore. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For readers tracking ALIVUS Share Price Today, the most useful next checks are the valuation backdrop, sector benchmark and whether the share price rise remains aligned with the broader healthcare peer set on Univest.

ALIVUS Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,433.95
Previous Close	Rs 1,351.25
Today's Move	Rs 82.7 (+6.12%)
Open	Rs 1,251
High	Rs 1,433.95
Low	Rs 1,251
Turnover	Rs 0.47 crore
Market Capitalisation	Rs 16,589.49 crore
Market Cap Category	Mid Cap

Glenmark Life Sciences Ltd. (ALIVUS) rose to Rs 1,433.95 from the previous close of Rs 1,351.25, a move of Rs 82.7 or 6.12%. The stock opened at Rs 1,251, reached a high of Rs 1,433.95, recorded a low of Rs 1,251.

ALIVUS Share Price opened at Rs 1,251, touched a day low of Rs 1,251 and finished at the day high of Rs 1,433.95. That means the stock rose Rs 82.70, or 6.12%, versus the previous close of Rs 1,351.25. The move was clean within the day’s range because the close matched the high and the low matched the open. In stock market today terms, Glenmark Life Sciences Ltd. stood out as a rising today name without any verified company-specific trigger in the supplied data. Investors following ALIVUS Stock News can therefore focus on the measured price action, current valuation and sector context rather than an unverified headline cause. Univest tracks the same session move in a structured way for readers who want a concise ALIVUS Share Price summary.

Glenmark Life Sciences Ltd. (ALIVUS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 16,589.49 crore
P/E Ratio	27.51x
P/B Ratio	4.76x
ROE	18.41%
ROCE	24.61%
EPS	Rs 49.12
Book Value Per Share	Rs 283.86
Dividend Yield	0.37%

Glenmark Life Sciences Ltd. (ALIVUS) fundamental metrics show P/E 27.51x, P/B 4.76x, ROE 18.41%, ROCE 24.61%. These figures provide context only and are not a buy or sell signal.

Glenmark Life Sciences Ltd. has a market capitalisation of Rs 16589.49 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 27.51x, P/B at 4.76x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.41% and ROCE of 24.61%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 49.12, book value per share of Rs 283.86, dividend yield of 0.37%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.21x, median ROE of 11.78%, median ROCE of 13.6%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	27.51x
Benchmark Median P/E	31.21x
Benchmark Average P/E	48.1x
Benchmark P/E Range	3.7x to 672.45x
Company P/B Ratio	4.76x
Benchmark Median P/B	2.88x
Company ROE	18.41%
Benchmark Median ROE	11.78%
Company ROCE	24.61%
Benchmark Median ROCE	13.6%
Company Market Capitalisation	Rs 16,589.49 crore
Benchmark Median Market Cap	Rs 670.73 crore

Glenmark Life Sciences Ltd. (ALIVUS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 27.51x, which is below the benchmark median of 31.21x, a difference of -11.86%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Glenmark Life Sciences Ltd. (ALIVUS) has a ROE of 18.41%, which is above the benchmark median of 11.78%, a difference of +56.28%. Glenmark Life Sciences Ltd. (ALIVUS) has a ROCE of 24.61%, which is above the benchmark median of 13.6%, a difference of +80.96%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries Ltd.	SUNPHARMA	4,60,696.31	38.09	5.33	14.85	19.11
Divi's Laboratories Ltd.	DIVISLAB	2,46,062.83	84.12	13.93	16.19	21.51
Torrent Pharmaceuticals Ltd.	TORNTPHARM	1,91,515.22	87.81	21.34	26.76	19.27
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,18,403.7	26.24	4.39	19.69	21.39
Cipla Ltd.	CIPLA	1,14,554.33	33.99	3.26	11.83	16

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 27.51x compared with the displayed peer median of 38.09x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.41% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 24.61% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glenmark Life Sciences Ltd. (ALIVUS) has a market capitalisation of Rs 16,589.49 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching ALIVUS

• ALIVUS Share Price rose 6.12% today to Rs 1,433.95, with the close at the day high.
• Market capitalisation stands at Rs 16,589.49 crore, placing Glenmark Life Sciences Ltd. above the industry median.
• P/E is 27.51 and P/B is 4.76, which gives ALIVUS Share Price a clear valuation frame.
• ROE of 18.41% and ROCE of 24.61% are both above the same-industry median.
• Turnover was Rs 0.47 crore, and the session move is visible without a verified company-specific catalyst.

About Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd., now tracked on the market as ALIVUS, operates in the Pharmaceuticals & Drugs industry within Healthcare. The company’s listing context places it in a sector where investors often compare profitability, valuation and scale across a wide set of peers. Based on the supplied data, the business should be viewed through its market capitalisation, earnings profile and industry benchmark rather than through a narrow price move alone. For readers following ALIVUS Share Price, the company overview is best understood alongside its current financial ratios: EPS of Rs 49.12, book value of Rs 283.86 and dividend yield of 0.37%. Univest uses that same fact base to keep ALIVUS Stock News and ALIVUS Company News tied to measurable market data.

Track ALIVUS Share Price on Univest

Use Glenmark Life Sciences Ltd. (ALIVUS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Readers can track ALIVUS Share Price on Univest for live share price, fundamental ratios, shareholding pattern, 52-week levels and broader market insights. The platform also helps compare ALIVUS Stock Analysis with peer benchmarks, sector context and market cap data in one place. If you are following ALIVUS Share Price Today, Univest keeps the latest data organised for quick review. That makes it easier to monitor ALIVUS Share Price Live, ALIVUS Share News and ALIVUS Latest News without losing the financial context behind the day’s move.

Frequently Asked Questions

Why did ALIVUS Share Price rise today?

Ans. The supplied data confirms a 6.12% rise to Rs 1,433.95, but it does not establish a company-specific catalyst. The move is still useful to track because the close matched the intraday high.

What is the current ALIVUS Share Price?

Ans. ALIVUS Share Price is Rs 1,433.95. It gained Rs 82.70 from the previous close of Rs 1,351.25, which makes today’s session a clear same-day price rise. The previous close was Rs 1,351.25.

What is the market capitalisation of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a market capitalisation of Rs 16,589.49 crore. That figure shows company size in the market and helps frame ALIVUS Share Price against healthcare peers. The company operates in the Healthcare sector.

How does ALIVUS look on valuation?

Ans. ALIVUS trades at a P/E of 27.51 and P/B of 4.76. Compared with the same-industry median P/E of 31.21, the earnings multiple is lower, while book value multiples sit higher.

How strong are the profitability ratios for ALIVUS?

Ans. ALIVUS reports ROE of 18.41% and ROCE of 24.61%. Both are above the same-industry medians of 11.78% and 13.6%, giving the share price move important profitability context. ROE stands at 18.41%.

How does ALIVUS compare with its peers?

Ans. Against peers such as Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, ALIVUS has a smaller market cap but a lower P/E than several larger names. Comparable listed companies include Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Torrent.

Can investors track ALIVUS Share Price on Univest?

Ans. Yes. Univest tracks ALIVUS Share Price with live price data, fundamental ratios, shareholding pattern, 52-week levels and market insights so readers can review the stock in a single place. The previous close was Rs 1,351.25.